Poxel Gets $17.1 Million to Advance Type 2 Diabetes Drug Trial

Poxel SA has raised 13 million euros ($17.1 million) in venture backing, which it plans to use to start a mid-stage clinical trial for its experimental Type 2 diabetes drug.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.